Voyager Therapeutics (VYGR) EBITDA Margin (2015 - 2026)

Voyager Therapeutics has disclosed EBITDA Margin across 12 years of filings, most recently posting 1088.78% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 1088.78%, down 61473.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 319.14% (down 19325.0% YoY), and the FY2025 annual result was 295.44%, down 21374.0% from the prior year.
• EBITDA Margin came in at 1088.78% for Q1 2026 at Voyager Therapeutics, down from 178.23% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 1516.65% in Q4 2022 to a low of 3252.89% in Q1 2022.
• The 5-year median for EBITDA Margin is 206.45% (2025), against an average of 502.35%.
• Across the five-year window, EBITDA Margin sank 292005 bps in 2022 and soared 333538 bps in 2023, its largest moves.
• Voyager Therapeutics' EBITDA Margin stood at 1516.65% in 2022, then slumped by 96 bps to 62.81% in 2023, then sank by 981 bps to 553.26% in 2024, then soared by 68 bps to 178.23% in 2025, then slumped by 511 bps to 1088.78% in 2026.
• The last three EBITDA Margin figures came in at 1088.78% (Q1 2026), 178.23% (Q4 2025), and 206.45% (Q3 2025), per Business Quant data.